CN111432826A - 用于治疗抗生素耐药性的组合物和方法 - Google Patents

用于治疗抗生素耐药性的组合物和方法 Download PDF

Info

Publication number
CN111432826A
CN111432826A CN201880078163.8A CN201880078163A CN111432826A CN 111432826 A CN111432826 A CN 111432826A CN 201880078163 A CN201880078163 A CN 201880078163A CN 111432826 A CN111432826 A CN 111432826A
Authority
CN
China
Prior art keywords
composition
species
antibiotic resistance
bacteria
abundance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880078163.8A
Other languages
English (en)
Chinese (zh)
Inventor
C·B·福德
J·布赖恩特
E·J·奥布莱恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seres Therapeutics Inc
Original Assignee
Seres Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seres Therapeutics Inc filed Critical Seres Therapeutics Inc
Publication of CN111432826A publication Critical patent/CN111432826A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880078163.8A 2017-10-30 2018-10-30 用于治疗抗生素耐药性的组合物和方法 Pending CN111432826A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762578698P 2017-10-30 2017-10-30
US62/578,698 2017-10-30
US201862741346P 2018-10-04 2018-10-04
US62/741,346 2018-10-04
PCT/US2018/058279 WO2019089643A1 (en) 2017-10-30 2018-10-30 Compositions and methods for treating antibiotic resistance

Publications (1)

Publication Number Publication Date
CN111432826A true CN111432826A (zh) 2020-07-17

Family

ID=64607291

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880078163.8A Pending CN111432826A (zh) 2017-10-30 2018-10-30 用于治疗抗生素耐药性的组合物和方法

Country Status (11)

Country Link
US (2) US12214002B2 (https=)
EP (1) EP3703720A1 (https=)
JP (1) JP2021501185A (https=)
KR (1) KR20200079292A (https=)
CN (1) CN111432826A (https=)
AU (1) AU2018360561A1 (https=)
BR (1) BR112020008552A2 (https=)
CA (1) CA3080586A1 (https=)
MX (1) MX2020004495A (https=)
RU (1) RU2020117775A (https=)
WO (1) WO2019089643A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164526A (zh) * 2018-07-19 2021-07-23 潘德勒姆治疗公司 用于微生物植入的方法和组合物
CN116042432A (zh) * 2022-07-14 2023-05-02 沈阳医学院 一种具有广谱抑菌性的新菌种及其抑菌物质的提纯
WO2023134365A1 (zh) * 2022-01-17 2023-07-20 中国科学院上海营养与健康研究所 调控脂质吸收的方法、组合物及其应用

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
SG11201503966PA (en) 2012-11-23 2015-06-29 Seres Health Inc Synergistic bacterial compositions and methods of production and use thereof
JP2016509003A (ja) 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 組成物および方法
US10973861B2 (en) 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
WO2014145958A2 (en) 2013-03-15 2014-09-18 Seres Health, Inc. Network-based microbial compositions and methods
CN105979952B (zh) 2013-11-25 2022-04-08 赛里斯治疗公司 协同细菌组合物以及其制造方法和用途
AU2017249159B2 (en) 2016-04-11 2024-06-13 President And Fellows Of Harvard College Probiotic formulations for improving athletic performance
EP3668527A1 (en) 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
BR112020008552A2 (pt) * 2017-10-30 2020-12-29 Seres Therapeutics, Inc. métodos e composições para tratamento de resistência a antibiótico
MX2020010177A (es) * 2018-03-29 2021-01-15 Seres Therapeutics Inc Composiciones y métodos para tratar enfermedades inflamatorias intestinales.
BR112020023933A2 (pt) * 2018-05-24 2021-04-27 Seres Therapeutics, Inc. composições bacterianas projetadas e usos destas
CA3145904A1 (en) 2019-07-05 2021-01-14 4D Pharma Research Limited Compositions comprising bacterial strains
GB201911728D0 (en) * 2019-08-15 2019-10-02 Genome Res Ltd Bacterial composistions for the treatment of disease
CN111157722B (zh) * 2019-11-25 2022-10-11 广州惠善医疗技术有限公司 生物标志物的用途
WO2021108643A1 (en) * 2019-11-25 2021-06-03 Fitbiomics Inc. Compositions for improving athletic performance and methods of use thereof
GB202007452D0 (en) 2020-05-19 2020-07-01 Microbiotica Ltd Threrapeutic bacterial composition
TW202214276A (zh) * 2020-06-11 2022-04-16 美商艾弗洛生物科技股份有限公司 使用ｈａｒｒｙｆｌｉｎｔｉａ ａｃｅｔｉｓｐｏｒａ治療疾病和障礙之組成物及方法
EP4201415A4 (en) * 2020-08-14 2024-08-21 Kobiolabs, Inc. FAECALIBACTERIUM PRAUSNITZII STRAIN AND USES THEREOF
CN116847859A (zh) 2020-09-11 2023-10-03 奇迹生物公司 微生物组组合物的方法和用途
CN114807348B (zh) * 2022-04-21 2024-05-07 济南大学 长链非编码rna lra-1及其干扰rna在治疗动脉粥样硬化中的应用
JP1779660S (https=) 2024-05-09 2024-09-11
JP1779661S (https=) 2024-05-09 2024-09-11
KR102874308B1 (ko) * 2024-09-09 2025-10-22 (주)에이스바이옴 신규한 리모실락토바실러스 퍼멘텀 abf21069 균주와 이를 포함하는 비알코올성 지방간 질환의 예방, 개선 및 항염활성 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140328803A1 (en) * 2013-02-04 2014-11-06 Seres Health, Inc. Compositions and Methods
US20160030494A1 (en) * 2013-03-15 2016-02-04 Seres Therapeutics, Inc. Network-Based Microbial Compositions and Methods
US20160158295A1 (en) * 2013-02-04 2016-06-09 Seres Therapeutics, Inc. Compositions and Methods
US20170087196A1 (en) * 2014-05-19 2017-03-30 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing clostridium difficile infection
WO2017091783A2 (en) * 2015-11-24 2017-06-01 Seres Therapeutics, Inc. Designed bacterial compositions
US20170354697A1 (en) * 2016-06-14 2017-12-14 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection

Family Cites Families (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3009864A (en) 1958-09-18 1961-11-21 Union Carbide Corp Process control
US3228838A (en) 1959-04-23 1966-01-11 Union Carbide Corp Preservation of biological substances
US3009861A (en) 1961-01-13 1961-11-21 Alderton Gordon Isolation of bacterial spores
US3608030A (en) 1969-05-21 1971-09-21 Howard Tint Method of preparing a tablet dosage-form for the immunization of the intestinal tract with live virus preparations
US4077227A (en) 1976-11-12 1978-03-07 Regents Of The University Of Minnesota Method of freezing liquid material in which agglomeration is inhibited
US4205132A (en) 1978-07-17 1980-05-27 Microlife Technics, Inc. Lyophilization of bacteria
FI59925C (fi) 1980-01-11 1981-11-10 Esko Viljo Nurmi Foerfarande foer framstaellning av ett bakteriepreparat anvaendbart foer foerhindrande av salmonellainfektion hos fjaederfae
US4780987A (en) 1983-10-25 1988-11-01 Plant Genetics, Inc. Method for the preparation of hydrated, pregerminated seeds in gel capsules
US4655047A (en) 1985-03-25 1987-04-07 I.Q.F. Inc. Process for freezing or chilling
US4839281A (en) 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
DE3887353T2 (de) 1987-10-12 1994-05-05 Capability Services Pty Ltd Behandlungsverfahren für magen-darm-krankheiten.
US5045446A (en) 1988-08-26 1991-09-03 Cryopharm Corporation Lyophilization of cells
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
DE68928665T2 (de) 1988-08-02 1998-11-12 Gastro Services Pty Ltd Behandlung von gastro-intestinalen krankheiten
GB2233343B (en) 1989-06-30 1993-07-07 Farmos Oy A bacterial preparation for use in poultry
JP2961182B2 (ja) 1990-03-09 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
JP2961184B2 (ja) 1990-05-07 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
US5436002A (en) 1991-01-29 1995-07-25 Mycogen Corporation Bacillus thuringiensisisolate PS201T6 toxin
RU2035186C1 (ru) 1992-07-09 1995-05-20 Семен Рафаилович Резник Профилактический биопрепарат споролакт
ES2157225T3 (es) 1992-10-09 2001-08-16 Advanced Tissue Sciences Inc Celulas hepaticas de reserva.
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
US5851545A (en) 1995-08-25 1998-12-22 Sandoz Ltd. Insecticidal matrix and process for preparation thereof
ES2248822T3 (es) 1995-09-15 2006-03-16 Dale N. Gerding Procedimientos y composiciones para la prevencion y el tratamiento de enfermedades asociadas al clostridium difficile.
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
AUPO430496A0 (en) 1996-12-19 1997-01-23 Arnott's Biscuits Limited Prebiotics and probiotics
US5965128A (en) 1997-08-13 1999-10-12 University Of Georgia Research Foundation Inc. Control of enterohemorrhagic E. coli 0157:H7 in cattle by probiotic bacteria and specific strains of E. coli
US5951977A (en) 1997-10-14 1999-09-14 The United States Of America, As Represented By The Secretary Of Agriculture Competitive exclusion culture for swine
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
FI106042B (fi) 1999-07-12 2000-11-15 Tekno Forest Oy Vedenpuhdistusmenetelmä, siihen soveltuvia bakteereja ja niiden käyttö
US6589771B1 (en) 1999-10-28 2003-07-08 Immunom Technologies, Inc. Methods for arousing dormant bacteria
US20030118547A1 (en) 2000-01-27 2003-06-26 Vandenberg Grant William Composition for intestinal delivery
AU2001233529A1 (en) 2000-02-10 2001-08-20 Andrew W. Bruce Probiotic therapy for newborns
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
AU2100402A (en) 2000-11-30 2002-06-11 Bio Balance Corp Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
KR100437497B1 (ko) 2001-03-07 2004-06-25 주식회사 프로바이오닉 로타바이러스 및 유해 미생물 억제 활성을 가지는 신규내산성 락토바실러스 루테리 프로바이오-16 및 이를함유하는 생균활성제
CN1678735A (zh) 2001-05-04 2005-10-05 佛罗里达大学研究基金会有限公司 来源于细菌的丙酮酸脱羧酶(pdc)基因的克隆和测序及其用途
ITMI20011632A1 (it) 2001-07-27 2003-01-27 Sanofi Synthelabo Composizione solida contenente spore di batteri non patogeni del genere bacillus
GB0130789D0 (en) 2001-12-21 2002-02-06 King S College London Application of spores
US8383342B2 (en) 2002-04-24 2013-02-26 The University Of North Carolina At Greensboro Compositions, products, methods and systems to monitor water and other ecosystems
GB0212975D0 (en) 2002-06-06 2002-07-17 Mars Uk Ltd Mammalian animal composition
AU2002951692A0 (en) 2002-09-23 2002-10-17 Vital Biotech (Hong Kong) Limited Improvements in or relating to vaccines
AU2003303894A1 (en) 2003-01-30 2004-08-30 The Regents Of The University Of California Inactivated probiotic bacteria and methods of use thereof
WO2004101770A1 (en) 2003-03-13 2004-11-25 Universite De Moncton (Bureau De Soutien A L'innovation) Antioxidant producing bacterium and uses thereof
AU2004232362C1 (en) 2003-04-23 2008-05-29 E. R. Squibb & Sons, L.L.C. Compositions and methods for the therapy of inflammatory bowel disease
US20060046246A1 (en) 2003-04-24 2006-03-02 Qiandong Zeng Genus, group, species and/or strain specific 16S rDNA sequences
WO2004104175A2 (en) 2003-05-14 2004-12-02 University Of Georgia Research Foundation, Inc. Probiotic bacteria and methods
CA2535951A1 (en) 2003-08-14 2005-03-03 The Bio Balance Corporation Bacterial strains, compositions including same and probiotic use thereof
KR20060073937A (ko) 2003-08-18 2006-06-29 더 바이오 밸런스 코포레이션 안정한 액상 촉생제 조성물, 그의 제조 및 응용
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US20050048515A1 (en) 2003-08-29 2005-03-03 Garner Bryan E. Methods for detecting and quantifying specific probiotic microorganisms in animal feed
US20050239706A1 (en) 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
HUE024565T2 (hu) 2004-02-03 2016-02-29 Prevtec Microbia Inc Élõ baktériumok alkalmazása növekedésserkentésre állatokban
US7632520B2 (en) 2004-02-16 2009-12-15 Sanjeev Khandelwal Synergistic antibacterial formulation and to a method of making the same
US7854927B2 (en) 2004-05-11 2010-12-21 Ganeden Biotech, Inc. Methods and compositions for the dietary management of autoimmune disorders
PL1812585T3 (pl) 2004-11-01 2015-03-31 Erber Ag Bakteriofagi jako czynniki selekcyjne
US20090197249A1 (en) 2004-11-01 2009-08-06 George Mason University Compositions and methods for diagnosing colon disorders
US20060188523A1 (en) 2005-01-10 2006-08-24 Zhiheng Pei Methods for diagnosing and treating chronic tonsillitis
US7627437B2 (en) 2005-01-14 2009-12-01 Idaho Research Foundation Categorization of microbial communities
JP4977124B2 (ja) 2005-03-25 2012-07-18 ウニベルズィタイト・ヘント フラボノイド類の酵素的脱メチル化
US7993667B2 (en) 2005-03-25 2011-08-09 Kimberly-Clark Worldwide, Inc. Methods of manufacturing a medicated tampon assembly
AU2006253007B2 (en) 2005-05-31 2012-12-20 Alimentary Health Ltd Feline probiotic Bifidobacteria
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
EP1931363B1 (en) 2005-09-28 2015-11-18 Nordisk Rebalance A/S Treatment of ibd using both probiotic bacteria and fermented cereal as treatment effectors
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
JP2009537138A (ja) 2006-05-18 2009-10-29 バイオバランス エルエルシー 細菌株、この細菌株を含む組成物およびそのプロバイオティック使用
US20090324638A1 (en) 2006-06-12 2009-12-31 Biopeptides Corp. Live bacterial vaccine
JP5019563B2 (ja) 2006-06-16 2012-09-05 旭化成ケミカルズ株式会社 腸内細菌賦活剤
RU2009101475A (ru) 2006-06-20 2010-07-27 Конинклейке Филипс Электроникс, Н.В. (Nl) Электронная капсула и способ для лечения желудочно-кишечного заболевания
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
EE05459B1 (et) 2006-12-08 2011-08-15 Tartu �likool Sporogeense Bacillus smithii tvi TBMI12 MSCL P737 ja selle endospooride kasutamine probiootikumina, toidulisandina ning probiootiline kompositsioon
EP2102350A4 (en) 2006-12-18 2012-08-08 Univ St Louis DARMMICROBIOMA AS A BIOMARKER AND THERAPEUTIC OBJECT FOR THE TREATMENT OF ADIPOSITAS OR ADIPOSITASCONDUCTIVE DISEASES
DE102006062250A1 (de) 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
WO2008083157A2 (en) 2006-12-29 2008-07-10 Washington University In St. Louis Altering pgc-1alapha, ampk, fiaf, or the gastrointestinal microbiota as a means to modulate body fat and/or weight loss in a subject
WO2009036121A1 (en) 2007-09-12 2009-03-19 Targanta Therapeutics Corp. Method of inhibiting clostridium difficile by administration of oritavancin
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
US8236508B2 (en) 2008-01-29 2012-08-07 Drexel University Detecting and measuring live pathogens utilizing a mass detection device
US8021654B2 (en) 2008-03-14 2011-09-20 Danisco A/S Methods of treating pigs with Bacillus strains
RU2010144789A (ru) 2008-04-01 2012-05-10 Метаметрикс Клиникал Лэборетери (Us) Процесс и способ мониторинга желудочно-кишечной микрофлоры
CN101264107A (zh) 2008-05-09 2008-09-17 东北制药集团公司沈阳第一制药厂 地衣芽孢杆菌药物组合物及其制剂
CN102940652B (zh) 2008-05-28 2015-03-25 青岛东海药业有限公司 两形真杆菌制剂及其应用
WO2010007106A1 (en) 2008-07-15 2010-01-21 Metanomics Health Gmbh Means and methods diagnosing gastric bypass and conditions related thereto
CN102131928A (zh) 2008-08-26 2011-07-20 奥林巴斯株式会社 粪便试样的调制方法、粪便试样调制用溶液、及粪便采集用试剂盒
WO2010030997A1 (en) 2008-09-12 2010-03-18 The Washington University Regulating intestinal microbiota dependent signaling as a means to modulate body fat and/or weight loss
US9603876B2 (en) 2008-09-25 2017-03-28 New York University Compositions and methods for restoring gastrointestinal microbiota following antibiotic treatment
JP5620392B2 (ja) 2008-11-03 2014-11-05 タフツ ユニヴァーシティーＴｕｆｔｓ Ｕｎｉｖｅｒｓｉｔｙ クロストリジウム・ディフィシレ胞子の発芽および伸長を阻害するための方法および組成物
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
IT1392672B1 (it) 2009-01-12 2012-03-16 Wyeth Consumer Healthcare S P A Composizioni comprendenti componenti probiotici e prebiotici e sali minerali, con lactoferrina
IT1393931B1 (it) 2009-02-25 2012-05-17 Neuroscienze Pharmaness S C A R L Composizione di spore di batteri non patogeni
BRPI1013829A2 (pt) 2009-04-20 2019-09-24 Qteros Inc composições e métodos para fermentação de biomassa
US20120128633A1 (en) 2009-04-30 2012-05-24 Campagnie Gervaise Donone Use of collinsella aerofaciens for reducing bloating
HRP20160598T4 (hr) 2009-05-01 2019-06-28 Uas Laboratories Llc Bakterijski sastavi za prevenciju i liječenje degenerativne bolesti
JP2010280640A (ja) 2009-06-08 2010-12-16 Kirin Holdings Co Ltd 穀類植物種子由来の不溶性食物繊維を含有する大腸癌予防用物質
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
US20120165215A1 (en) 2009-06-26 2012-06-28 The Regents Of The University Of California Methods and systems for phylogenetic analysis
WO2011046614A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods and systems for phylogenetic analysis
WO2011005756A1 (en) 2009-07-06 2011-01-13 Puretech Ventures, Llc Delivery of agents targeted to microbiota niches
CN102695427B (zh) 2009-08-18 2016-04-13 雀巢产品技术援助有限公司 包含乳球菌属菌株并且特别是在婴儿和儿童中减少过敏症状的营养组合物
WO2011022542A2 (en) 2009-08-19 2011-02-24 Puretech Ventures, Llc Administration of factors normally present in a microbial niche to improve health
US20120149584A1 (en) 2009-08-21 2012-06-14 Bernat Olle Methods of diagnosing and treating microbiome-associated disease using interaction network parameters
GB0916335D0 (en) 2009-09-17 2009-10-28 Martin W J Medicaments
PL2480255T3 (pl) 2009-09-23 2018-07-31 Thomas Julius Borody Terapia przewlekłych zakażeń jelitowych
CA2776420A1 (en) 2009-10-05 2011-04-14 Aak Patent B.V. Methods for diagnosing irritable bowel syndrome
US20110081320A1 (en) 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
WO2011046616A2 (en) 2009-10-15 2011-04-21 New York University Methods for modulating bacterial infection
WO2011060123A1 (en) 2009-11-12 2011-05-19 Nestec S.A. Nutritional composition for promoting gut microbiota balance and health
AU2010339573B2 (en) 2009-12-31 2014-08-28 Ira Milton Trachtman Compositions and method for treatment and prophylaxis of inflammatory bowel disease
DK3564357T3 (da) 2010-02-01 2022-06-20 Rebiotix Inc Bakterieterapi mod clostridium difficile colitis
US9492487B2 (en) 2010-02-01 2016-11-15 Matthew Ryan Garner Microbial product containing multiple microorganisms
WO2011103123A2 (en) 2010-02-16 2011-08-25 Arizona Technology Enterprises Reducing short-chain fatty acids and energy uptake in obese humans by managing their intestinal microbial communities
US20130045874A1 (en) 2010-03-01 2013-02-21 Institut National De La Recherche Agronomique Method of Diagnostic of Inflammatory Bowel Diseases
US20130005586A1 (en) 2010-03-01 2013-01-03 Stanislav Ehrlich Method of diagnostic of obesity
IT1398553B1 (it) 2010-03-08 2013-03-01 Probiotical Spa Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
WO2011113801A1 (en) 2010-03-16 2011-09-22 Universiteit Gent Use of clostridium perfringens strain 23 to protect against necrotic enteritis
US8951512B2 (en) 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
EP2591114B1 (en) 2010-07-06 2016-06-08 GlaxoSmithKline Biologicals SA Immunisation of large mammals with low doses of rna
WO2012009712A2 (en) 2010-07-16 2012-01-19 The Board Of Trustees Of The University Of Arkansas Methods and compositions including spore-forming bacteria for increasing the health of animals
US8980279B2 (en) 2010-07-26 2015-03-17 Qu Biologics Personalized site-specific immunomodulation
FI20105825A7 (fi) 2010-07-26 2012-01-27 Suomen Punainen Risti Veripalvelu Veriryhmästatuksen käyttö III
EP3424515A3 (en) 2010-08-04 2019-06-19 Thomas Julius Borody Stool collection devices and methods for using them
US9386793B2 (en) 2010-08-20 2016-07-12 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
EP2613802A4 (en) 2010-09-10 2014-03-26 Viropharma Inc ENVIRONMENTAL CLOSTRIDAL BACTERIOTHERAPY AND ASSOCIATED FORMULATIONS AND METHODS OF MAKING AND USING SAME
EP2646567A4 (en) 2010-10-04 2014-03-26 British Columbia Cancer Agency DETECTION OF FUSOBACTERIUM IN A GASTROINTESTINAL SAMPLE FOR THE DIAGNOSIS OF GASTROINTESTINAL CARCINOMA
US8802099B2 (en) 2010-11-10 2014-08-12 National Jewish Health Methods to treat allergic conditions
US20120064592A1 (en) 2011-01-26 2012-03-15 Qteros, Inc. Biocatalysts synthesizing deregulated cellulases
CN103491969A (zh) 2011-02-09 2014-01-01 拉维沃公司 恢复和重建肠道微生物群的合生素组合物
US8511540B2 (en) 2011-02-18 2013-08-20 Echostar Technologies L.L.C. Matrix code for use in verification of data card swap
AR085409A1 (es) 2011-02-25 2013-10-02 Tricorder Diagnostics Llc Firmas microbianas como indicadores de exposicon a radiacion
WO2012122522A2 (en) 2011-03-09 2012-09-13 Washington University Cultured collection of gut microbial community
US9968638B2 (en) 2011-03-09 2018-05-15 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
WO2012142605A1 (en) 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
US20120276056A1 (en) 2011-04-26 2012-11-01 Wieslaw Janusz Bochenek Method for Use of Biologic Agents Including Live or Dormant Forms of Bacteria and other organisms in Treating Infections, Inflammation and Other Diseases of Distal Small Intestine and Large Intestine
US20120278201A1 (en) 2011-04-26 2012-11-01 Dwolla Corp. Location transaction processing system
WO2012159023A2 (en) 2011-05-19 2012-11-22 Virginia Commonwealth University Gut microflora as biomarkers for the prognosis of cirrhosis and brain dysfunction
US9579353B2 (en) 2011-06-10 2017-02-28 Prothera, Inc. Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
WO2013008102A2 (en) 2011-07-14 2013-01-17 R.E.D. Laboratories N.V../ S.A. Methods and compositions for evaluating and/or treating chronic immune diseases
US20130022575A1 (en) 2011-07-19 2013-01-24 Microbial Rx Systems and methods of replacing intestinal flora
WO2013016636A1 (en) 2011-07-27 2013-01-31 Max International, Llc Compositions comprising sugar-cysteine products
WO2013019896A1 (en) 2011-08-01 2013-02-07 Symbiotix Biotherapies, Inc. Platform for identifying and/or characterizing immunomodulatory agents
KR101982491B1 (ko) 2011-08-30 2019-05-27 아카데미쉬 메디쉬 센트륨 인슐린 저항 예방 및/또는 치료 방법
US20140363397A1 (en) 2011-09-14 2014-12-11 Queen's University At Kingston Method for treatment of disorders of the gastrointestinal system
US20130121968A1 (en) 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles
US20130115232A1 (en) 2011-10-03 2013-05-09 Fred Hutchinson Cancer Research Center Methods for detecting graft-versus-host disease
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CN103857402A (zh) 2011-10-11 2014-06-11 阿基姆医药公司 包括厌氧培养的人类肠道微生物群的组合物
ES2993669T3 (en) 2011-12-01 2025-01-03 Univ Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
GB201201766D0 (en) 2012-02-01 2012-03-14 Imp Innovations Ltd Method
WO2013121573A1 (ja) 2012-02-17 2013-08-22 住友商事株式会社 ソフトバイオマスの分解方法
US20150125883A1 (en) 2012-04-30 2015-05-07 Washington University Method of isolating and characterizing microorganisms that are targets of host immune responses
US10130665B2 (en) 2012-05-18 2018-11-20 Genome Research Limited Method for identifying bacteria for bacteriotherapy
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
AU2013266069B2 (en) 2012-05-25 2018-03-15 Sloan Kettering Institute For Cancer Research Methods for treating GI syndrome and graft versus host disease
EP2684469A1 (en) 2012-07-13 2014-01-15 Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO Methods for strengthening and assessment of the natural defence of the colon against C. difficile overgrowth
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
SG11201503966PA (en) 2012-11-23 2015-06-29 Seres Health Inc Synergistic bacterial compositions and methods of production and use thereof
WO2014088982A1 (en) 2012-12-07 2014-06-12 Albert Einstein College Of Medicine Of Yeshiva University Gut barrier dysfunction treatment and prevention
EP2971148A4 (en) 2013-03-14 2016-08-17 Seres Therapeutics Inc METHODS OF DETECTING PATHOGENS AND ENRICHING FROM MATERIALS AND COMPOSITIONS
EP2991659B1 (en) 2013-05-03 2018-10-10 Nestec S.A. Lachnospiraceae in the gut microbiota and association with body weight
WO2015018307A1 (en) 2013-08-06 2015-02-12 Bgi Shenzhen Co., Limited Biomarkers for colorectal cancer
CN105979952B (zh) 2013-11-25 2022-04-08 赛里斯治疗公司 协同细菌组合物以及其制造方法和用途
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
WO2016086161A1 (en) 2014-11-25 2016-06-02 Memorial Sloan-Kettering Cancer Center Intestinal microbiota and gvhd
EP3319619A4 (en) 2015-07-08 2019-01-02 Seres Therapeutics, Inc. Methods of treating colitis
US10300043B2 (en) 2015-08-12 2019-05-28 Mayo Foundation For Medical Education And Research Method for treating a gastrointestinal disorder in a mammal using bacteroides thetaiotaomicron and compositions thereof
AU2016318112B2 (en) 2015-09-04 2021-11-04 Memorial Sloan-Kettering Cancer Center Methods and compositions for detecting risk of cancer relapse
WO2017074257A1 (en) 2015-10-26 2017-05-04 Nanyang Technological University Non-viable derivatives of clostridium sporogenes as anti-cancer therapeutic agents
WO2017091753A1 (en) 2015-11-25 2017-06-01 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing vancomycin-resistant enterococci infection or colonization
KR20180094950A (ko) 2015-12-14 2018-08-24 메타보겐 에이비 간내 담즙정체증 및 관련 간 질환들의 치료
EP3429604A1 (en) 2016-03-14 2019-01-23 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
WO2017160944A2 (en) 2016-03-15 2017-09-21 The Regents Of The University Of Michigan Compositions and methods for treating and preventing graft versus host disease
PL3445380T6 (pl) 2016-04-19 2025-05-05 Genome Research Limited Bakterioterapia
CA3226196A1 (en) 2016-06-14 2017-12-21 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
KR102708641B1 (ko) 2016-09-27 2024-09-24 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 미생물유전체를 조정함으로써 면역 체크포인트 차단 요법을 증강시키는 방법
EP3668527A1 (en) 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
BR112020006731A2 (pt) 2017-10-03 2020-12-01 Seres Therapeutics, Inc. manipulação do metabolismo da triptamina
BR112020008552A2 (pt) 2017-10-30 2020-12-29 Seres Therapeutics, Inc. métodos e composições para tratamento de resistência a antibiótico
KR20250162624A (ko) 2018-01-23 2025-11-18 더 제너럴 하스피탈 코포레이션 미토콘드리아 기능 개선을 위한 조성물 및 방법
EP3773915A2 (en) 2018-03-28 2021-02-17 Seres Therapeutics, Inc. Treatment of a cancer by microbiome modulation
MX2020010177A (es) 2018-03-29 2021-01-15 Seres Therapeutics Inc Composiciones y métodos para tratar enfermedades inflamatorias intestinales.
BR112020023933A2 (pt) * 2018-05-24 2021-04-27 Seres Therapeutics, Inc. composições bacterianas projetadas e usos destas
KR20210100662A (ko) 2018-12-05 2021-08-17 세레스 테라퓨틱스, 인코포레이티드 박테리아를 안정화시키는 조성물 그리고 이의 용도
BR112022010411A2 (pt) 2019-11-27 2022-08-23 Seres Therapeutics Inc Composições bacterianas projetadas e usos das mesmas

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140328803A1 (en) * 2013-02-04 2014-11-06 Seres Health, Inc. Compositions and Methods
US20160158295A1 (en) * 2013-02-04 2016-06-09 Seres Therapeutics, Inc. Compositions and Methods
US20160030494A1 (en) * 2013-03-15 2016-02-04 Seres Therapeutics, Inc. Network-Based Microbial Compositions and Methods
US20170087196A1 (en) * 2014-05-19 2017-03-30 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing clostridium difficile infection
WO2017091783A2 (en) * 2015-11-24 2017-06-01 Seres Therapeutics, Inc. Designed bacterial compositions
US20170354697A1 (en) * 2016-06-14 2017-12-14 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KHANNA S 等: "A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection", 《J INFECT DIS》 *
PENG Z 等: "Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing", 《J CLIN MICROBIOL》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164526A (zh) * 2018-07-19 2021-07-23 潘德勒姆治疗公司 用于微生物植入的方法和组合物
WO2023134365A1 (zh) * 2022-01-17 2023-07-20 中国科学院上海营养与健康研究所 调控脂质吸收的方法、组合物及其应用
CN116042432A (zh) * 2022-07-14 2023-05-02 沈阳医学院 一种具有广谱抑菌性的新菌种及其抑菌物质的提纯

Also Published As

Publication number Publication date
US20250288625A1 (en) 2025-09-18
BR112020008552A2 (pt) 2020-12-29
RU2020117775A (ru) 2021-12-01
CA3080586A1 (en) 2019-05-09
EP3703720A1 (en) 2020-09-09
AU2018360561A1 (en) 2020-05-21
KR20200079292A (ko) 2020-07-02
US20200353018A1 (en) 2020-11-12
US12214002B2 (en) 2025-02-04
MX2020004495A (es) 2021-01-08
JP2021501185A (ja) 2021-01-14
WO2019089643A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
CN111432826A (zh) 用于治疗抗生素耐药性的组合物和方法
Wei et al. Enterococcus faecium: evolution, adaptation, pathogenesis and emerging therapeutics
Duche et al. Antibiotic resistance in potential probiotic lactic acid bacteria of fermented foods and human origin from Nigeria
JP7359758B2 (ja) トリプタミン代謝の操作
Segal et al. Lung microbiome for clinicians. New discoveries about bugs in healthy and diseased lungs
Rossi et al. Occurrence and species level diagnostics of Campylobacter spp., enteric Helicobacter spp. and Anaerobiospirillum spp. in healthy and diarrheic dogs and cats
Said et al. Emergence of multidrug resistance and extensive drug resistance among enterococcal clinical isolates in Egypt
de Madaria et al. Detection and identification of bacterial DNA in serum from patients with acute pancreatitis
Ranjan et al. Molecular epidemiology and genome dynamics of New Delhi metallo-β-lactamase-producing extraintestinal pathogenic Escherichia coli strains from India
Bessesen et al. MRSA colonization and the nasal microbiome in adults at high risk of colonization and infection
Sun et al. IgA-targeted Lactobacillus jensenii modulated gut barrier and microbiota in high-fat diet-fed mice
Omeershffudin et al. Emerging threat of antimicrobial resistance in Neisseria gonorrhoeae: pathogenesis, treatment challenges, and potential for vaccine development
Rangaraju et al. Occurrence, antimicrobial resistance and virulence properties of thermophilic Campylobacter coli originating from two different poultry settings
Hamza et al. Genotyping and antimicrobial resistance patterns of Helicobacter pylori in human and dogs associated with A2142G and A2143G point mutations in clarithromycin resistance
Bujňáková et al. Distribution of virulence-associated genes, antibiotic resistance and phylogenetic groups in Escherichia coli isolated from domestic and racing pigeons
Scupham et al. Antibiotic manipulation of intestinal microbiota to identify microbes associated with Campylobacter jejuni exclusion in poultry
Dalwadi et al. Whole-genome sequencing of bacteria accountable for lactational mastitis in humans combined with an examination of their antibiotic resistance profiles
Le Guern et al. First isolation of Yersinia entomophaga in human urinary tract
Dube et al. Molecular characterization and antibiotic resistance patterns of avian fecal Escherichia coli from turkeys, geese, and ducks
KR101384745B1 (ko) 병원성 유전자를 포함한 항생제 내성 Ｅ. ｃｏｌｉ 균주
Jaradat et al. Virulence, antimicrobial susceptibility and phylogenetic analysis of Cronobacter sakazakii isolates of food origins from Jordan
Mai et al. Fecal carriage and molecular epidemiology of mcr-1-harboring Escherichia coli from children in southern China
Gahamanyi et al. High prevalence of antibiotic resistant Campylobacter among patients attending clinical settings in Kigali, Rwanda
Ashton et al. Interplay between the gut microbiome and typhoid fever: insights from endemic countries and a controlled human infection model
Maeda et al. Prevalence, antimicrobial susceptibility, and virulence profiles of fluoroquinolone-resistant Escherichia coli isolated from companion animals in Sapporo, Japan

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200717